Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | CAD | P27708 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26940602 | 1.00 | L3MBTL1 (0.42) | L3MBTL1KMT2APOLBNOD1ALDH1A1 | |
| SCHEMBL30682247 | 0.92 | L3MBTL1 (0.39) | L3MBTL1KMT2APOLBNOD1ALDH1A1 | |
| SCHEMBL30682331 | 0.92 | L3MBTL1 (0.34) | L3MBTL1KMT2APOLB | |
| SCHEMBL26940594 | 0.91 | TSHR (0.34) | L3MBTL1ALDH1A1HSD17B10FAAH | |
| SCHEMBL26941258 | 0.91 | TSHR (0.34) | L3MBTL1ALDH1A1HSD17B10FAAH | |
| SCHEMBL26941094 | 0.91 | L3MBTL1 (0.33) | L3MBTL1KMT2APOLBCTSLCTSB | |
| SCHEMBL26941131 | 0.91 | L3MBTL1 (0.33) | L3MBTL1KMT2APOLBCTSLCTSB | |
| SCHEMBL26941126 | 0.90 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL26941092 | 0.90 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL26930062 | 0.90 | FAAH (0.30) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577201-B2 | Glutamine analogs | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4229029-B1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2026-02-25 | — | — | EP | claimed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | claimed |
| US-12577201-B2 | Glutamine analogs | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| EP-4229029-B1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2026-02-25 | — | — | EP | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577201-B2 | Glutamine analogs | GLUL, GLS, GLS2 | L3MBTL1 2128/4885KMT2A 1721/4885POLB 1541/4885 |
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | L3MBTL1 2866/4885KMT2A 907/4885POLB 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.